To evaluate whether patients with CXCR5+CD8+T-high tumor might benefit more from ACT (±RT) compared with patients with CXCR5+CD8+T-low tumor, we investigated the association between CXCR5+CD8+T cells density and OS among patients with TNM II + III diseases who either did or did not receive ACT. Here, CD8A is linked to neoplasm.